{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadened antigen display in tumors, increasing the fraction of tumor proteins observed in the immunopeptidome.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "The report notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination was associated with an expanded MHC-I peptidome, consistent with increased antigen processing and presentation.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        },
        {
          "quote": "2. Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, limiting direct clinical extrapolation from these measurements."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling is a key mediator of the sensitization effect produced by intratumoral mRNA vaccination.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |",
          "line_ref": "L31"
        }
      ],
      "caveat": "The study includes perturbation controls, but mechanistic effects may still vary by tumor model and may not generalize across all settings."
    },
    {
      "claim_id": "C04",
      "claim": "Vaccination increased PD-L1 pathway activity in tumor tissue, providing a rationale for combining intratumoral mRNA vaccination with anti-PD-L1 therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Changes in PD-L1 expression do not by themselves prove improved clinical response, and the report emphasizes limits to causal interpretation."
    },
    {
      "claim_id": "C05",
      "claim": "In a retrospective metastatic patient cohort treated with ICIs, prior SARS-CoV-2 mRNA vaccination was associated with improved survival.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        },
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because the human comparison is retrospective with variable vaccination timing and heterogeneous tumors/treatment histories, the association cannot be interpreted as causal."
    }
  ]
}
